-
Markeder
-
Aksjer
Sustainable finance2025 Euronext ESG Trends ReportLes merA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indekser
Access the white paperInvesting in the future of Europe with innovative indicesLes merThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETF-er
The European market place for ETFsEuronext ETF EuropeLes merInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fond
-
Obligasjoner
European Defence BondsGroupe BPCE lists the first bondLes merFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Strukturerte produkter
-
Derivater
Where European Government Bonds Meet the FutureFixed Income derivativesLes merTrade mini bond futures on main European government bonds
-
Råvarer
- Oversikt
- Quotes snapshot
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Levering og oppgjør
- Spesifikasjoner og ordninger
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesLes merEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Ressurser
Designed to help students navigate the complexities of financial marketsEuronext Trading gameLes merJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
CARMAT
Identification
Listing sponsor / Agent
Dexia Securities France
ISIN code
FR0010907956
Exchange / Market
Euronext Growth
Handelssted
Paris
ICB
Medical Equipment
Activity description
Créée le 30 juin 2008, CARMAT SAS est une Jeune Entreprise Biomédicale Innovante financée par TRUFFLE CAPITAL, EADS et le Professeur Carpentier avec le soutien d’OSEO.
L’objectif de Carmat est de proposer un cœur artificiel totalement implantable, incluant les ventricules droit et gauche et dont la conception vise à se rapprocher au maximum du cœur humain. Comptant près de 15 années de développement, ce projet est issu de la collaboration du chirurgien cardio-vasculaire Alain Carpentier et de EADS, dans la mise en œuvre de biomatériaux et de technologies de pointe appliquées au domaine du cœur artificiel.
Website address
http://www.carmatsas.com
Issuer website
http://www.carmatsas.com
Operation
IPO date
ons 07/07/2010
IPO type
Initial Public offering
Catégorie
IPO